Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04285268
Title Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

relapsed/refractory diffuse large B-cell lymphoma

B-cell lymphoma

Burkitt lymphoma

lymphoma

Therapies

Bortezomib + Rituximab + Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.